To further evaluate the regulation of MAGI2 in glomerular diseases, we included in our study four different glomerulopathy animal models: The DOCA-salt hypertension heminephrectomy mouse model, the nephrotoxic serum nephritis mouse model, the puromycin aminonucleoside model, and zebrafish genetic podocytopathy models. This evidence concerns the gene MAGI2 and lipoprotein glomerulopathy.